Table 1.
Patients’ demographic, clinical, and biochemical data
| PMX | CONV | |
|---|---|---|
| Age (years) | 61 ± 10 | 59 ± 13 |
| Male N (%) | 6 (75) | 6 (75) |
| APACHE II | 21.2 ± 3.6 | 20.4 ± 4.4 |
| Site of infection N (%) | ||
| Abdominal | 7 (87) | 5(65) |
| Urinary tract | 1 (13) | 3(35) |
| Antibiotics N (%) | ||
| Glycopeptides | 4 (50) | 5 (62) |
| Aminoglycosides | 3 (37) | 4 (50) |
| SOFA score | ||
| T0 | 11 (13–7) | 9 (20–7) |
| T72 | 5.5 (11–2)a | 10.5 (23–6)d |
| RIFLE N (%) | ||
| Risk | ||
| T0 | 5 (62.5) | 5 (62.5) |
| T72 | 2 (25) | 2 (25) |
| Injury | ||
| T0 | 2 (25) | 1 (12.5) |
| T72 | 0 | 1 (12.5) |
| Failure | ||
| T0 | 0 | 0 |
| T72 | 0 | 1(12.5) |
| Risk + injury + failure | ||
| T0 | 7 (87) | 6 (75) |
| T72 | 2 (25)b | 4 (50) |
| Patients on catecholamine N (%) | ||
| T0 | 8 (100) | 8(100) |
| T72 | 3 (37)c | 7 (87) |
| Noradrenaline (μg/kg/min) | ||
| T0 | 0.5 (1.0–0.1) | 0.45 (0.8–0.08) |
| T72 | 0 (0.4–0)a | 0.12 (0.8–0) |
| LPS (pg/ml) | ||
| T0 | 187.83 ± 21.45 | 162.57 ± 37.87 |
| T72 | 87.74 ± 19.45a | 184.63 ± 30.56 |
| TNF-alpha (pg/ml) | ||
| T0 | 84.53 ± 19.85 | 76.53 ± 16.32 |
| T72 | 21.34 ± 7.98a | 95.34 ± 19.64 |
Data are expressed as mean ± SD and median (range)
PMX polymyxin-B, CONV conventional, APACHE II acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, RIFLE risk, injury, failure, loss of function, end stage
aWilcoxon Signed Rank test PMX: T0 versus T72, P = 0.02
bFisher Exact test PMX: T0 versus T72, P = 0.04
cFisher Exact test: PMX versus CONV at T72, P = 0.02
dMann–Whitney test: PMX T72 versus CONV T72, P = 0.02